IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Vazquez Martin, Alejandro ^a,b   Cufí, Sílvia ^a,b   Oliveras Ferraros, Cristina ^a,b   Torres Garcia, Violeta Zenobia ^a,b   Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   Bonavia, Rosa ^c   Visa, Joana ^c   Martin Castillo, Begoña ^a,b   Barrajón Catalán, Enrique ^d,e   Micol, Vicente ^d,e   Bosch Barrera, Joaquim ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e MONTELOEDER S L   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; QUINAZOLINE DERIVATIVE; SOMATOMEDIN C RECEPTOR;

ARTICLE; DRUG EFFECT; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE DELETION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME; TUMOR CELL LINE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; EXONS; GENES, ERBB-1; HUMANS; QUINAZOLINES; RECEPTOR, IGF TYPE 1; SEQUENCE DELETION; TREATMENT OUTCOME;

EID: 84884199186     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02560     Document Type: Article

References (59)

1. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl JMed 350, 2129-39 (2004). (Pubitemid 38637993)
2. Paez, J. G. et al. EGFRmutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-500 (2004). (Pubitemid 38720929)
3. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101, 13306-11 (2004). (Pubitemid 39209661)
4. Mitsudomi, T. & Yatabe, Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98, 1817-24 (2007). (Pubitemid 350002184)
5. Riely, G. J., Politi, K. A., Miller, V. A. & Pao, W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12, 7232-41 (2006). (Pubitemid 46095394)
6. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-67 (2009).
7. Riely, G. J. et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12, 839-44 (2006). (Pubitemid 43259866)
8. Jackman, D. M. et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12, 3908-14 (2006). (Pubitemid 44078074)
9. Kobayashi, S. et al. EGFRmutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-92 (2005). (Pubitemid 40271173)
10. Pao, W. et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2, e73 (2005).
11. Kwak, E. L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102, 7665-70 (2005). (Pubitemid 40741028)
12. Balak, M. N. et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12, 6494-501 (2006). (Pubitemid 44799723)
13. Kosaka, T. et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12, 5764-9 (2006). (Pubitemid 44629607)
14. Morgillo, F., Bareschino, M. A., Bianco, R., Tortora, G. & Ciardiello, F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75, 788-99 (2007). (Pubitemid 350086168)
15. Nguyen, K. S., Kobayashi, S. & Costa, D. B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10, 281-9 (2009).
16. Lin, L. & Bivona, T. G. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract 2012, 817297 (2012).
17. Engelman, J. A. et al.METamplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). (Pubitemid 46799492)
18. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104, 20932-7 (2007).
19. Suda, K. et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16, 5489-98 (2010).
20. Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118, 2609-19 (2008). (Pubitemid 351949788)
21. Kokubo, Y. et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in Lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92, 1711-9 (2005). (Pubitemid 40756483)
22. Yamasaki, F. et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67, 5779-88 (2007). (Pubitemid 46985011)
23. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44, 852-60 (2012).
24. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26 (2011).
25. Thomson, S. et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65, 9455-62 (2005). (Pubitemid 41508014)
26. Fuchs, B. C. et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68, 2391-9 (2008). (Pubitemid 351521814)
27. Yauch, R. L. et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11, 8686-98 (2005). (Pubitemid 43005918)
28. Coldren, C. D. et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4, 521-8 (2006). (Pubitemid 44341362)
29. Suda, K. et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6, 1152-61 (2011).
30. Chung, J. H. et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 73, 176-82 (2011).
31. Cortot, A. B. et al. Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Res 73, 834-43 (2013).
32. Karp, D. D. et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27, 2516-22 (2009).
33. Gualberto, A. & Pollak, M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-21 (2009).
34. Gualberto, A. et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16, 4654-65 (2010).
35. Kim, H. J. et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27, 3165-75 (2007).
36. Inoue, A. et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2, 279-88 (2002). (Pubitemid 41043962)
37. Kajita, M.,McClinic, K. N. &Wade, P. A. Aberrant expression of the transcription factors Snail and Slug alters the response to genotoxic stress. Mol Cell Biol 24, 7559-66 (2004). (Pubitemid 39121483)
38. Wu, W. S. et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123, 641-53 (2005).
39. Leroy, P. & Mostov, K. E. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell 18, 1943-52 (2007). (Pubitemid 46717573)
40. Oliveras-Ferraros, C. et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11, 4020-32 (2012).
41. Yao, Z. et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107, 15535-40 (2010).
42. Chang, T. H. et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 183, 1071-9 (2011).
43. Frederick, B. A. et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6, 1683-91 (2007). (Pubitemid 46954044)
44. Witta, S. E. et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66, 944-5 (2006).
45. Bryant, J. L. et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 106, 148-56 (2012).
46. Byers, L. A. et al. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19, 279-290 (2013).
47. Post-White, J., Ladas, E. J. & Kelly, K. M. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 6, 104-9 (2007). (Pubitemid 46871842)
48. Gazák, R., Walterová, D. & Kren, V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14, 315-38 (2007).
49. Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R. P. & Agarwal, B. B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26, 4457-98 (2006). (Pubitemid 46031522)
50. Singh, R. P. & Agarwal, R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45, 436-42 (2006). (Pubitemid 43865852)
51. Rho, J. K. et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 9, 3233-43 (2010).
52. Singh, R. P., Raina, K., Sharma, G. & Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14, 7773-80 (2008).
53. Wu, K. et al. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep 23, 1545-52 (2010).
54. Deep, G., Gangar, S. C., Agarwal, C. & Agarwal, R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 4, 1222-32 (2011).
55. Zi, X., Zhang, J., Agarwal, R. & Pollak, M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60, 5617-20 (2000).
56. Liu, W. et al. Interference of silibinin with IGF-1R signalling pathways protects human epidermoid carcinoma A431 cells from UVB-induced apoptosis. Biochem Biophys Res Commun 432, 314-9 (2013).
57. Cao, X. et al. In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles. Int J Nanomedicine 7, 753-62 (2012).
58. Morgillo, F., Woo, J. K., Kim, E. S., Hong, W. K. & Lee, H. Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66, 10100-11 (2006). (Pubitemid 44672064)
59. Shien, K. et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051-61 (2013).